TY  - JOUR
AU  - Shrivastava, Amit Kumar
AU  - Shrestha, Laxmi
AU  - Pokhrel, Buddhi Raj
AU  - Joshi, Bishal
AU  - Lamichhane, Gopal
AU  - Vidović, Bojana
AU  - Koirala, Niranjan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4990
AB  - The aim of this study was to identify the bioactive phytoconstituents present in the aqueous extract of Nigella sativa and also, to evaluate the antioxidant and antihyperlipidemic activity in Wistar rats. The LC-MS/MS analysis was assessed for the determination of different bioactive compounds present in N. sativa extract. Total phenolic and flavonoid content were determined by using validated Folin-Ciocalteu and Aluminum chloride colorimetric methods, respectively. The in-vitro antioxidant and in-vivo antihyperlipidemic activity in Wistar rats were also evaluated. Preliminary phytochemical screening of the extract showed the presence of alkaloids, flavonoids, phenols, glycosides, and amino acids in the aqueous extract. The bioactive compounds of the aqueous extract were identified through LC-MS/MS analysis. The in-vitro antioxidant activity of N. sativa showed the highest free radical scavenging capacity in DPPH, H2O2, and OH radical scavenging assays with IC50 values 11.916 ± 2.828, 30.294 ± 13.790, and 12.048 ± 2.828 µg/mL, respectively. Evaluation of antihyperlipidemic activity of extract in Wistar rats showed that a high dose (800 mg/kg) of extract significantly decreased total cholesterol (TC) 71.76 ± 6.91 mg/dL, TG 83.6 ± 8.09 mg/dL, low-density lipoproteins (LDL-c) 33.86 ± 6.05 mg/dL, very low-density lipoproteins (VLDL-c) 16.72 ± 1.61 mg/dL level in blood. However, the HDL-C level was significantly improved (21.18 ± 1.80 mg/dL) as compared to HFD-induced control rats (11.76 ± 1.14 mg/dL) after 28 days of treatment. Also, at the same dose, animal body weight was also decreased to 162.6 ± 16.40 g compared with control 184.4 ± 10.24 g. The aqueous extract of N. sativa was found to be an effective natural source of antioxidant and hypolipidemic agents. This activity was attributed to the presence of diverse bioactive compounds in it. © 2023 The Authors. eFood published by John Wiley & Sons Australia, Ltd on behalf of International Association of Dietetic Nutrition and Safety.
PB  - John Wiley and Sons Inc
T2  - eFood
T1  - LC-MS based metabolite profiling, in-vitro antioxidant and in-vivo antihyperlipidemic activity of Nigella sativa extract
VL  - 4
IS  - 4
DO  - 10.1002/efd2.107
ER  - 

@article{
author = "Shrivastava, Amit Kumar and Shrestha, Laxmi and Pokhrel, Buddhi Raj and Joshi, Bishal and Lamichhane, Gopal and Vidović, Bojana and Koirala, Niranjan",
year = "2023",
abstract = "The aim of this study was to identify the bioactive phytoconstituents present in the aqueous extract of Nigella sativa and also, to evaluate the antioxidant and antihyperlipidemic activity in Wistar rats. The LC-MS/MS analysis was assessed for the determination of different bioactive compounds present in N. sativa extract. Total phenolic and flavonoid content were determined by using validated Folin-Ciocalteu and Aluminum chloride colorimetric methods, respectively. The in-vitro antioxidant and in-vivo antihyperlipidemic activity in Wistar rats were also evaluated. Preliminary phytochemical screening of the extract showed the presence of alkaloids, flavonoids, phenols, glycosides, and amino acids in the aqueous extract. The bioactive compounds of the aqueous extract were identified through LC-MS/MS analysis. The in-vitro antioxidant activity of N. sativa showed the highest free radical scavenging capacity in DPPH, H2O2, and OH radical scavenging assays with IC50 values 11.916 ± 2.828, 30.294 ± 13.790, and 12.048 ± 2.828 µg/mL, respectively. Evaluation of antihyperlipidemic activity of extract in Wistar rats showed that a high dose (800 mg/kg) of extract significantly decreased total cholesterol (TC) 71.76 ± 6.91 mg/dL, TG 83.6 ± 8.09 mg/dL, low-density lipoproteins (LDL-c) 33.86 ± 6.05 mg/dL, very low-density lipoproteins (VLDL-c) 16.72 ± 1.61 mg/dL level in blood. However, the HDL-C level was significantly improved (21.18 ± 1.80 mg/dL) as compared to HFD-induced control rats (11.76 ± 1.14 mg/dL) after 28 days of treatment. Also, at the same dose, animal body weight was also decreased to 162.6 ± 16.40 g compared with control 184.4 ± 10.24 g. The aqueous extract of N. sativa was found to be an effective natural source of antioxidant and hypolipidemic agents. This activity was attributed to the presence of diverse bioactive compounds in it. © 2023 The Authors. eFood published by John Wiley & Sons Australia, Ltd on behalf of International Association of Dietetic Nutrition and Safety.",
publisher = "John Wiley and Sons Inc",
journal = "eFood",
title = "LC-MS based metabolite profiling, in-vitro antioxidant and in-vivo antihyperlipidemic activity of Nigella sativa extract",
volume = "4",
number = "4",
doi = "10.1002/efd2.107"
}

Shrivastava, A. K., Shrestha, L., Pokhrel, B. R., Joshi, B., Lamichhane, G., Vidović, B.,& Koirala, N.. (2023). LC-MS based metabolite profiling, in-vitro antioxidant and in-vivo antihyperlipidemic activity of Nigella sativa extract. in eFood
John Wiley and Sons Inc., 4(4).
https://doi.org/10.1002/efd2.107

Shrivastava AK, Shrestha L, Pokhrel BR, Joshi B, Lamichhane G, Vidović B, Koirala N. LC-MS based metabolite profiling, in-vitro antioxidant and in-vivo antihyperlipidemic activity of Nigella sativa extract. in eFood. 2023;4(4).
doi:10.1002/efd2.107 .

Shrivastava, Amit Kumar, Shrestha, Laxmi, Pokhrel, Buddhi Raj, Joshi, Bishal, Lamichhane, Gopal, Vidović, Bojana, Koirala, Niranjan, "LC-MS based metabolite profiling, in-vitro antioxidant and in-vivo antihyperlipidemic activity of Nigella sativa extract" in eFood, 4, no. 4 (2023),
https://doi.org/10.1002/efd2.107 . .